A poster of Al-Kaisy’s Virgin Back (ie. front-line ahead of spine surgery) feasibility trial shows efficacy continuing to improve out through 3 years. 12 month data was just published last week in Neuromodulation on 20 patients that showed back pain VAS reduced from 7.9 at baseline to 2.3 at 12 months with a 90% responder rate (VAS reduction of ≥50%). ODI scores, which measure functional improvements, declined 48% from baseline with 45% of patients in the minimal disability category at 12 months with 90% of patients reported satisfaction with Senza therapy. Further, sleep disturbances decreased 54% (p